Lung Cancer Update

Featuring an interview with Dr Jamie E Chaft, including the following topics: Case: A man in his early 70s with a 40 to 50 pack-year history of smoking and cT2bN1 squamous cell carcinoma of the lung with PD-L1 60% treated with induction therapy and surgery (00:00) Available clinical data with immunotherapy in the neoadjuvant, perioperative and adjuvant settings (07:45) Factors in the selection of...

Featuring perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics: Introduction (0:00) Overview of Antibody-Drug Conjugates (ADCs) (2:07) Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23) Currently Available ADCs for Gynecologic Cancer Management (26:37) Currently...

Featuring perspectives from Dr Lyudmila Bazhenova and Dr Corey J Langer, including the following topics: Introduction (0:00) Therapeutic Approaches Targeting HER2 and RET — Dr Bazhenova (9:09) Therapeutic Approaches Targeting ALK and ROS1 — Dr Langer (31:56) CME information and select publications

Featuring perspectives from Dr Jonathan Goldman and Dr Zofia Piotrowska, including the following topics: Introduction (0:00) Current Management of Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Dr Goldman (0:38) Nonmetastatic EGFR-Mutated NSCLC, Exon 20 Insertion Mutations and Novel Agents — Dr Piotrowska (33:20) CME information and select publications

Featuring an interview with Prof Martin Reck, including the following topics: Case: A woman in her mid 70s with extensive-stage small cell lung cancer (ES-SCLC) experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (0:00) Biology of small cell lung cancer and pharmacodynamics of systemic treatment (3:25) Considerations with maintenance therapy fo...

Dr Christine L Hann from the Johns Hopkins University School of Medicine in Baltimore, Maryland, and Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss key clinical trial data surrounding the management of SCLC. CME information and select publications

Dr Suresh S Ramalingam and Dr Helena Yu discuss the selection and sequencing of therapy for patients with EGFR mutation-positive non-small cell lung cancer and summarize major advances in the treatment landscape reported over the past year. CME information and select publications here .

Dr Natalie Vokes from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of lung cancer. CME information and select publications here .

Dr Hossein Borghaei from Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Anne Chiang from Yale Cancer Center in New Haven, Connecticut, discuss key clinical trial data in the first-line management of ES-SCLC, real-world case studies and current patterns of care among oncologists. CME information and select publications here .

Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid and Dr Shields from Indiana University School of Medicine in Indianapolis discuss key datasets surrounding first-line and maintenance therapy for patients with extensive-stage small cell lung cancer and their clinical implications.  CME information and select publications here .

Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields summarize the treatment landscape and review relevant clinical datasets for patients with lung cancer. CME information and select publications here .

Dr John Heymach from The University of Texas MD Anderson Cancer Center in Houston discusses recent updates on available and novel treatment strategies for HER2-altered non-small cell lung cancer.    CME information and select publications here .

Dr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer.  CME information and select publications here .

Dr Aaron Lisberg from the University of California, Los Angeles discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer.  CME information and select publications here .

Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer.  CME information and select publications here .

Dr Stephen V Liu from Georgetown University Hospital in Washington, DC and Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York discuss the role of approved and novel investigational therapies for patients with limited-stage and extensive-stage small cell lung cancer.  CME information and select publications here .

Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer.  CME information and select publications here .

Dr Benjamin Levy from Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial in Washington, DC, discusses important efficacy and safety data from 2024 related to the use of approved and investigational therapies for localized and advanced non-small cell lung cancer without a targetable mutation.  CME information and select publications here .

Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations.  CME information and select publications here .

Dr Anne Chiang, Dr Erin Schenk, and nurse practitioners Ms Elizabeth Krueger and Ms Beth Sandy discuss the role of bispecific antibodies in the management of small cell lung cancer and strategies to mitigate and manage treatment-emergent adverse events.  NCPD information and select publications here .

Prof Nicolas Girard, Dr Jonathan Goldman, Dr Pasi Jänne, Dr Suresh Ramalingam, Dr Joshua Sabari and moderator Dr Helena Yu present data informing treatment decision-making for EGFR-mutated NSCLC at the 2025 ASCO annual meeting.  CME information and select publications here .

Dr Jessica J Lin from Massachusetts General Hospital in Boston and Dr Joel W Neal from Stanford Cancer Institute in California summarize major treatment advances over the past year and review relevant ongoing clinical trials using targeted therapies for patients with non-small cell lung cancer.  CME information and select publications here .

Clinical investigators discuss available data guiding the management of non-small cell lung cancer with immunotherapy and other nontargeted approaches.   CME information and select publications here .

Clinical investigators discuss available data guiding the management of EGFR mutation-positive non-small cell lung cancer.   CME information and select publications here .

Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events.  NCPD information and select publications here .